Genetically modified “hunter” T cells successfully migrated to and penetrated a deadly type of brain tumor known as glioblastoma (GBM) in a clinical trial of the new therapy, but the cells triggered an immunosuppressive tumor microenvironment and faced a complex mutational landscape that will need to be overcome to better treat this aggressive cancer.
Cardiology Researcher Wins AHA Outstanding Early Career Investigator Award
Penn Center for Precision Medicine Awards $565,000 in Second Accelerator Grants
Breast Cancer Patients Can Use Antiperspirants During Radiotherapy
Offer of $100 Boosts Rates of Colon Cancer Screenings
Michael Phelps’ Race with a Great White During Shark Week: Does He Stand a Chance?
What America’s Corporations Can Do To Tackle Alzheimer’s
Miami Boy’s Death Shows Powerful Opioid’s Chilling Potential
Protect Yourself Against C. Diff Infections
Why Does Hunger Vanish When You Ignore It Long Enough?
New Gene Discoveries Could Redefine Alzheimer’s Treatment